Showing results (751-760 of 3,698) with videos related to
Sort By:
Pageof 370
International Journal of Clinical Oncology|August 6, 2022
Dedifferentiation in low-grade osteosarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) studyToshihide Hirai, Hiroshi Kobayashi, Eisuke Kobayashi, et al.International Journal of Clinical Oncology|August 9, 2022
The role of anti-tumor immunity of focused ultrasound for the malignancies: depended on the different ablation categoriesLuping Zhang, Chao Yang, Yixing Gao, et al.International Journal of Clinical Oncology|November 7, 2022
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumorsSusana Campos, Ursula Matulonis, Suzanne Berlin, et al.International Journal of Clinical Oncology|September 19, 2021
Impact of prostate-specific antigen screening on tumor size in patients with prostate cancer in a super-aging district in Kyoto, JapanToru Matsugasumi, Koji Okihara, Masashi Tsujimoto, et al.International Journal of Clinical Oncology|May 23, 2020
Progress on treatment of MET signaling pathway in non-small cell lung cancerXiaoqing Yu, Sizhe Yu, Yun FanInternational Journal of Clinical Oncology|May 27, 2020
Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysisKeiichiro Mori, Noriyoshi Miura, Hadi Mostafaei, et al.International Journal of Clinical Oncology|May 21, 2020
Risk factors for metachronous colorectal cancer in Lynch syndrome patients: a registry-based observational mono-institutional study cohortStefano Signoroni, Guglielmo Niccolò Piozzi, Maria Teresa Ricci, et al.International Journal of Clinical Oncology|June 24, 2020
Correction to: Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapySatoru Iwasa, Toshihiro Kudo, Daisuke Takahari, et al.International Journal of Clinical Oncology|June 5, 2020
Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trialsHisato Kawakami, Kazumasa Fujitani, Jin Matsuyama, et al.International Journal of Clinical Oncology|February 1, 2023
Prognostic impact of HER2-low expression in HER2-negative breast cancer under different hormone receptor statusBin Xu, Jianguo Shen, Jun Shen, et al.Pageof 370